← All trials
NCT07312851
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 12, 2026
- Primary completion
- Jun 19, 2026
- Completion date
- Jun 19, 2026
- First posted
- Dec 31, 2025
- Last posted
- Dec 31, 2025
- Enrollment
- 186
- Arms / groups
- 14 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- ParexelCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.